ConcertAI is featured in an article on how AI can enhance drug development from candidate screening to trial management. “We develop AI models that read the record, compute a stage, and give an accuracy score based on everything that’s in the record—imaging reports, molecular reports, and things of that nature,” says CEO Jeff Elton, PhD. “We even arrange for analyses to accept data only if it is of a given accuracy.”